A best-evidence topic in vascular surgery was written according to a structured protocol. The question addressed was whether screening asymptomatic individuals for an abdominal aortic aneurysm (AAA) is feasible and improves disease-free survival. Seven studies presented the best evidence to answer the clinical question. The author, journal, date and country of publication, patient group studied, study type, relevant outcomes, results and limitations of the studies are tabulated. In total, four randomized population-based studies have evaluated ultrasound screening for AAA: two British studies, Multicentre Aneurysm Screening Study (MASS) and the Chichester trial, and one each in Viborg County, Denmark and Western Australia. Participants were randomized to receive an invitation to screen or not. The MASS trial randomized 67 770 men, followed participants over 10 years and concluded that screening would almost half AAA-related deaths in men aged 65-74 years. The smaller Chichester trial included only 6040 men but demonstrated a 42% reduction in AAA-related mortality at 5 years, with ongoing benefit at 15 years (11% reduction). The Viborg County trial recruited 12 639 men aged 64-73 years, showed a 66% reduction in AAA-related mortality over 14 years. Finally, the Western Australia trial evaluated 41 000 men but included an older population of 65-83 years old. No benefit was seen in this age group but subgroup analysis of men aged 65-74 showed a significant mortality benefit. Only a small or insignificant benefit in all-cause mortality was seen in any of these studies. A recent meta-analysis of these trials has shown a significant benefit in AAA-related mortality in the long term and concluded that AAA screening is superior to other established screening programmes. The cost-effectiveness of screening was assessed in the MASS and Viborg County trials and was found to be substantially below the cost threshold set by the National Institute of Clinical Excellence for acceptance of interventions. Quality of life was assessed in the MASS and in a case-control study and showed no adverse effects that outweigh the benefits. We concluded that ultrasound screening for AAAs has met all the criteria to become a screening programme and would substantially reduce disease-related death with no adverse effect on quality of life.
INTRODUCTION
A best-evidence topic was constructed according to a structured protocol. This protocol is fully described in the Interactive CardioVascular and Thoracic Surgery [1] .
Clinical scenario
A 67-year old man presented to the emergency department with clinical features of a ruptured abdominal aortic aneurysm (AAA) and became acutely shocked. Emergent operative intervention was unsuccessful and he died from massive haemorrhage. In considering this patient's management you wonder if it would be feasible to screen for AAAs and if this would have any impact on individual or group outcome. You resolve to check the literature.
Three-part question
In [asymptomatic patients] is [screening for abdominal aortic aneurysms] [beneficial (cost-effective, AAA-related mortality, allcause mortality, quality of life)]. [2] , the Chichester trial [3] , Viborg Country (Denmark) trial [4] and the Western Australia study [5] . The Chichester trial included and analysed women separately [6] . Four meta-analyses of these trials have been published before 2009 and all showed a significant short-to mid-term reduction in AAA-related mortality [7] [8] [9] [10] . However, with the exception of the review by Fleming et al. [10] , these meta-analyses suffered from errors, as commented on by several authors in the literature [11, 12] . Therefore, a meta-analysis published by Takagi et al. [13] , which took these errors into account and used more up-to-date follow-up data, was included here. One case-control study on quality of life was also reviewed [14] .
RESULTS
The four randomized control trials evaluating the effects of ultrasound screening on AAA-related mortality and all-cause mortality recruited men aged 64-83 years from general practitioner (GP) lists or central databases [2] [3] [4] [5] . In the British studies, GPs excluded men considered unfit for surgery before randomization [2, 3] . All trials used computerized randomization of participants (1:1) to either receive or not receive invitations to screen. Attendance rates were between 63 and 80%. Evaluation of outcomes was based on intention-to-treat analysis. Mortality data were collected from a combination of hospital data and national registries. No significant loss to follow-up was reported in any of the trials. AAA was defined as ≥3 cm in diameter. The criteria for referral for surgery and intervals between surveillance scans varied between studies. The MASS trial recruited 67 770 men aged 65-74 years from four UK centres [2] . The investigators showed a persistent reduction in AAA-related mortality over 10 years and concluded that screening would almost half all aneurysm-related deaths. The earlier Chichester trial acted as a pilot to the MASS and demonstrated diminishing benefits even at 15 years of follow-up [3] . Both studies observed insignificant rises in AAA-related mortality in the later years of follow-up in men whose initial scans were normal, but concluded that rescanning was unjustified.
The Viborg County study from Denmark, which has a lower prevalence of AAA, confirmed the findings from the two UK trials, demonstrating that screening was beneficial in men aged 64-73 years in the long term [4] . This trial appointed an independent committee to assess the validity of death classifications and concluded that any misclassifications would generally bias against screening.
The Western Australia study enrolled more elderly men (aged 65-83 years) and attempted to emulate a national screening programme more realistically by recruiting directly from an electoral roll, without exclusions by GPs [5] . The findings showed that increasing co-morbidities, reduced acceptance (63%) and increased rupture rates make screening less beneficial in this elderly age group. However, sub-group analysis showed that the main benefit of screening was seen in men aged 65-75 years.
As AAA-related deaths correspond to approximately 2% of all deaths, all the trials only demonstrated a small or insignificant difference in all-cause mortality with AAA screening. Despite preferential blood pressure monitoring and smoking cessation advice for screened individuals in the MASS and Viborg trials, respectively, no general health advantages of screening were observed.
All meta-analysis performed on this subject have identified and analysed these four trials only. The most recent analysis by Takagi et al. [13] included only long-term (>10 years) follow-up data and concluded that screening would reduce AAA-related [2, 4] . Both concluded that AAA screening is highly cost-effective and well below the guideline figure (£25 000 per life-year gained) set by the National Institute of Clinical Excellence for acceptance of interventions in the NHS [15] . The cost-effectiveness increased over time as the main costs of the programme (screening and elective AAA repair) in the early years were offset by fewer expensive emergency operations.
Effects on quality of life as a result of screening were assessed through validated health questionnaires in the MASS trial and a case-control study [2, 14] . Both studies showed no adverse effects that outweigh the benefits.
The Chichester trial was the only trial to include women. Subgroup analysis had shown that screening was neither clinically indicated nor economically viable due to the low incidence of AAA in women. [6] Clinical bottom line
The AAA screening has met all the criteria to be a successful screening programme. It significantly reduces AAA-related mortality and is not harmful to the patients' self-perceived general health or well-being. It is also cost-effective to perform and is well below the figure set by the National Institute of Clinical Excellence for acceptance of interventions in the NHS. However, it is only beneficial for men aged 65-74 years and should be offered as a one-off ultrasound scan. A national screening programme, based closely on the procedures and protocol in the MASS, was launched in the UK in 2008 for all men turning 65 years of age. Similarly, AAA screening projects have been initiated in the USA [16, 17] .
